Owens & Minor Reports Fourth Quarter & Full Year Financial Results and Announces Sale Process Underway for Products & Healthcare Services Segment
Owens & Minor (NYSE: OMI) has announced significant financial developments and strategic initiatives. The company has achieved a total debt reduction of $647 million over two years, with $244 million reduced in 2024. The company is actively pursuing the sale of its Products & Healthcare Services (P&HS) segment and has authorized a $100 million share repurchase program over 24 months.
For 2025, OMI projects revenue between $10.85-11.15 billion, adjusted EBITDA of $560-590 million, and adjusted EPS of $1.60-1.85. The guidance indicates double-digit adjusted EBITDA and EPS growth with improving cash flow. The outlook excludes impacts from the announced Rotech acquisition, potential P&HS segment sale, and share repurchase activity.
Owens & Minor (NYSE: OMI) ha annunciato sviluppi finanziari significativi e iniziative strategiche. L'azienda ha raggiunto una riduzione totale del debito di 647 milioni di dollari in due anni, con una riduzione di 244 milioni di dollari nel 2024. L'azienda sta attivamente perseguendo la vendita del suo segmento Prodotti e Servizi Sanitari (P&HS) e ha autorizzato un programma di riacquisto di azioni da 100 milioni di dollari nell'arco di 24 mesi.
Per il 2025, OMI prevede ricavi compresi tra 10,85-11,15 miliardi di dollari, un EBITDA rettificato di 560-590 milioni di dollari e un EPS rettificato di 1,60-1,85 dollari. Le previsioni indicano una crescita a doppia cifra dell'EBITDA e dell'EPS rettificati, con un miglioramento del flusso di cassa. Le prospettive escludono gli impatti dall'acquisizione di Rotech annunciata, dalla potenziale vendita del segmento P&HS e dall'attività di riacquisto di azioni.
Owens & Minor (NYSE: OMI) ha anunciado desarrollos financieros significativos e iniciativas estratégicas. La compañía ha logrado una reducción total de deuda de 647 millones de dólares en dos años, con una reducción de 244 millones de dólares en 2024. La empresa está buscando activamente la venta de su segmento de Productos y Servicios de Salud (P&HS) y ha autorizado un programa de recompra de acciones de 100 millones de dólares durante 24 meses.
Para 2025, OMI proyecta ingresos entre 10,85-11,15 mil millones de dólares, EBITDA ajustado de 560-590 millones de dólares y EPS ajustado de 1,60-1,85 dólares. La guía indica un crecimiento de EBITDA y EPS ajustados de dos dígitos con un flujo de caja en mejora. Las perspectivas excluyen los impactos de la adquisición de Rotech anunciada, la posible venta del segmento P&HS y la actividad de recompra de acciones.
Owens & Minor (NYSE: OMI)는 중요한 재무 발전과 전략적 이니셔티브를 발표했습니다. 이 회사는 2년 동안 총 6억 4,700만 달러의 부채 감소를 달성했으며, 2024년에는 2억 4,400만 달러가 감소했습니다. 이 회사는 현재 제품 및 의료 서비스(P&HS) 부문의 매각을 적극적으로 추진하고 있으며, 1억 달러 규모의 자사주 매입 프로그램을 24개월 동안 승인했습니다.
2025년을 위해 OMI는 108.5억~111.5억 달러의 매출, 5억 6천만~5억 9천만 달러의 조정 EBITDA, 1.60~1.85 달러의 조정 EPS를 예상하고 있습니다. 이 가이드는 두 자릿수의 조정 EBITDA 및 EPS 성장과 개선되는 현금 흐름을 나타냅니다. 전망은 발표된 로텍 인수, 잠재적인 P&HS 부문 매각 및 자사주 매입 활동의 영향을 제외합니다.
Owens & Minor (NYSE: OMI) a annoncé des développements financiers significatifs et des initiatives stratégiques. L'entreprise a réalisé une réduction totale de la dette de 647 millions de dollars sur deux ans, avec une réduction de 244 millions de dollars en 2024. L'entreprise poursuit activement la vente de son segment Produits et Services de Santé (P&HS) et a autorisé un programme de rachat d'actions de 100 millions de dollars sur une période de 24 mois.
Pour 2025, OMI prévoit un chiffre d'affaires compris entre 10,85-11,15 milliards de dollars, un EBITDA ajusté de 560-590 millions de dollars et un BPA ajusté de 1,60-1,85 dollars. Les prévisions indiquent une croissance à deux chiffres de l'EBITDA et du BPA ajustés, avec une amélioration des flux de trésorerie. Les perspectives excluent les impacts de l'acquisition annoncée de Rotech, de la vente potentielle du segment P&HS et des activités de rachat d'actions.
Owens & Minor (NYSE: OMI) hat bedeutende finanzielle Entwicklungen und strategische Initiativen angekündigt. Das Unternehmen hat eine Gesamtschuldensenkung von 647 Millionen US-Dollar in zwei Jahren erreicht, wobei 244 Millionen US-Dollar im Jahr 2024 eingespart wurden. Das Unternehmen verfolgt aktiv den Verkauf seines Segments Produkte & Gesundheitsdienstleistungen (P&HS) und hat ein Aktienrückkaufprogramm über 100 Millionen US-Dollar über einen Zeitraum von 24 Monaten genehmigt.
Für 2025 prognostiziert OMI Einnahmen zwischen 10,85-11,15 Milliarden US-Dollar, ein bereinigtes EBITDA von 560-590 Millionen US-Dollar und einen bereinigten EPS von 1,60-1,85 US-Dollar. Die Prognose deutet auf ein zweistelliges Wachstum des bereinigten EBITDA und EPS mit verbessertem Cashflow hin. Die Aussichten schließen die Auswirkungen der angekündigten Rotech-Akquisition, den potenziellen Verkauf des P&HS-Segments und die Aktienrückkaufaktivitäten aus.
- Significant debt reduction of $647M over two years
- Projected double-digit adjusted EBITDA growth for 2025
- Expected revenue of $10.85-11.15B for 2025
- $100M share repurchase program authorized
- Goodwill impairment charge in Apria reporting unit
- Anticipated pricing changes in Apria's capitated contract
- High interest expense projection of $138-142M for 2025
Insights
Owens & Minor's strategic transformation is gaining momentum with several positive developments that reshape its financial trajectory. The $244 million debt reduction in 2024 (part of a $647 million two-year reduction) significantly strengthens the balance sheet, creating the financial flexibility needed for strategic initiatives like the Rotech acquisition. The 2025 guidance points to robust growth with projected revenue of $10.85-11.15 billion, adjusted EBITDA of $560-590 million, and adjusted EPS of $1.60-1.85 - all indicating double-digit growth in key profitability metrics.
The newly authorized $100 million share repurchase program represents a vote of confidence from management in their strategic direction while potentially providing support for the stock. The guidance projects improved cash flow and gross margins between 20.75-21.25%, suggesting operational efficiencies. However, investors should note the goodwill impairment charge in the Apria reporting unit, which was triggered by market conditions including OMI's stock price decline, rising interest rates, and anticipated pricing changes in a capitated contract. This non-cash charge signals some challenges within that business unit but doesn't affect underlying operations.
The potential divestiture of the Products & Healthcare Services segment represents a pivotal strategic shift, suggesting management sees greater long-term value in focusing on the higher-margin Patient Direct business. This restructuring aligns with their stated strategy of directing capital toward higher growth segments while improving overall financial metrics.
The announcement of an active sale process for the Products & Healthcare Services segment represents a transformational strategic pivot for Owens & Minor. This move would dramatically reshape the company into a more focused enterprise centered on its Patient Direct platform, which management clearly views as offering superior growth and margin potential. The timing appears opportunistic - having first strengthened the P&HS business by broadening its product portfolio and streamlining manufacturing, OMI has likely enhanced its attractiveness to potential buyers.
This potential divestiture coupled with the pending Rotech acquisition indicates a complete strategic realignment toward home healthcare services. The home care market benefits from powerful tailwinds: aging demographics, the shift toward home-based treatment options, and cost-containment pressures favoring out-of-hospital care. By doubling down on Patient Direct while potentially monetizing the P&HS segment, management is executing a classic portfolio optimization strategy.
The engagement of Citi as exclusive financial advisor suggests serious discussions are underway with potential buyers. The $100 million share repurchase authorization provides optionality - it could offset potential dilution from the Rotech purchase or signal management's belief that shares are undervalued ahead of this strategic transformation. However, executing two major transactions simultaneously (Rotech acquisition and P&HS divestiture) introduces execution risk that investors should monitor closely. The company has wisely excluded both transactions from its 2025 guidance, providing a clean baseline for evaluating organic performance while these strategic initiatives unfold.
Total Debt Reduction of
2025 Guidance Midpoint Indicates Double-Digit Adjusted EBITDA & Adjusted EPS Growth, and Improving Cash Flow
Active Discussions Well Underway Regarding Potential Sale of Products & Healthcare Services (P&HS) Segment
Board of Directors Authorizes Share Repurchase Program of Up to
“We are pleased with the progress that we have made against the strategy as outlined at our Investor Day in December 2023. As a reminder, we committed to optimizing our Products & Healthcare Services business, leveraging our leading Patient Direct platform, and building balance sheet flexibility through deleveraging. Within P&HS we continue to see momentum in broadening our product portfolio, developing a streamlined and efficient manufacturing footprint, and enhancing our distribution capabilities. Within Patient Direct, we continue to leverage our footprint and broad product offering to support home-based care for millions of patients with chronic conditions. These capabilities, combined with positive demographic trends and expanding home treatment options, leaves us very bullish on the future of this business. Finally, we repaid
Pesicka added, “Our commitment to directing capital toward the higher growth and higher margin Patient Direct segment has been increasingly evident in recent years and is consistent with our strategy. As a logical next step, we have been actively engaged in robust discussions regarding the potential sale of our Products & Healthcare Services segment.”
Pesicka concluded, “In the meantime, we remain focused on delivering a strong 2025 and are confident in our ability to achieve double-digit adjusted EBITDA growth while improving cash flow.”
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Financial Summary (1) (2) |
|
|
|
|
|
|
|
FYE |
|
FYE |
|||||
($ in millions, except per share data) |
|
4Q24 |
|
4Q23 |
|
2024 |
|
2023 |
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Revenue |
|
$ |
2,696 |
|
|
$ |
2,656 |
|
$ |
10,701 |
|
|
$ |
10,334 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Operating (loss) income, GAAP |
|
$ |
(262 |
) |
|
$ |
60 |
|
$ |
(208 |
) |
|
$ |
105 |
|
Adj. Operating Income, Non-GAAP |
|
$ |
95 |
|
|
$ |
111 |
|
$ |
313 |
|
|
$ |
305 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Net (loss) income, GAAP |
|
$ |
(296 |
) |
|
$ |
18 |
|
$ |
(363 |
) |
|
$ |
(41 |
) |
Adj. Net Income, Non-GAAP |
|
$ |
43 |
|
|
$ |
54 |
|
$ |
119 |
|
|
$ |
106 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Adj. EBITDA, Non-GAAP |
|
$ |
138 |
|
|
$ |
170 |
|
$ |
523 |
|
|
$ |
526 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Net (loss) income per common share, GAAP |
|
$ |
(3.84 |
) |
|
$ |
0.23 |
|
$ |
(4.73 |
) |
|
$ |
(0.54 |
) |
Adj. Net Income per share, Non-GAAP |
|
$ |
0.55 |
|
|
$ |
0.69 |
|
$ |
1.53 |
|
|
$ |
1.36 |
|
(1) Reconciliations of the differences between the non-GAAP financial measures presented in this release and their most directly comparable GAAP financial measures are included in the tables below. |
|||||||||||||||
(2) Non-GAAP results in this table exclude a goodwill impairment charge of |
|||||||||||||||
Share Repurchase Authorization
On February 26, 2025, the Owens & Minor Board of Directors authorized a share repurchase program of up to
2025 Financial Outlook
The Company issued its outlook for 2025; summarized below:
-
Revenue for 2025 to be in a range of
$10.85 billion $11.15 billion -
Adjusted EBITDA for 2025 to be in a range of
$560 million $590 million -
Adjusted EPS for 2025 to be in a range of
$1.60 $1.85
The Company’s outlook for 2025 excludes any impact of the previously announced Rotech acquisition, any potential transaction involving the Products & Healthcare Services segment, or share repurchase activity, and contains assumptions, including current expectations regarding the impact of general economic conditions.
Key assumptions supporting the Company’s 2025 financial guidance include:
-
Gross margin of
20.75% to21.25% -
Interest expense of
$138 million $142 million -
Adjusted effective tax rate of
29.0% to30.0% - Diluted weighted average shares of ~80 million
-
Capital expenditures, gross, of
$250 million $270 million - Stable commodity prices
- FX rates as of 12/31/2024
Although the Company does provide guidance for adjusted EBITDA and adjusted EPS (which are non-GAAP financial measures), it is not able to forecast the most directly comparable measures calculated and presented in accordance with GAAP without unreasonable effort. Certain elements of the composition of the GAAP amounts are not predictable, making it impracticable for the Company to forecast. Such elements include, but are not limited to, exit and realignment charges and acquisition-related charges, which could have a significant and unpredictable impact on our GAAP results. As a result, no GAAP guidance or reconciliation of the Company’s adjusted EBITDA guidance or adjusted EPS guidance is provided. The outlook is based on certain assumptions that are subject to the risk factors discussed in the Company’s filings with the SEC.
Financial Advisor
Citi is serving as exclusive financial advisor to Owens & Minor in connection with the potential sale of the Products & Healthcare Services (P&HS) segment.
Investor Conference Call for Fourth Quarter and Full Year 2024 Financial Results
Owens & Minor will host a conference call for investors and analysts on Friday, February 28, 2025, at 8:30 a.m. EST. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917. All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the investor relations page of the Owens & Minor website available at investors.owens-minor.com/events-and-presentations/. A replay of the webcast can be accessed following the presentation at the link provided above.
Safe Harbor
This release is intended to be disclosure through methods reasonably designed to provide broad, non-exclusionary distribution to the public in compliance with the SEC’s Fair Disclosure Regulation. This release contains certain “forward-looking” statements made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the statements in this release regarding our future prospects and performance, including our expectations with respect to our financial performance, our 2025 financial results, Owens & Minor’s ability to successfully complete the sale of the P&HS business in any specific transaction on favorable terms or at all, our ability to raise additional financing for our acquisition of Rotech on favorable terms or at all, the risk that the proposed acquisition of Rotech will not be consummated in a timely manner or at all, our cost-saving initiatives, future indebtedness and growth, industry trends, as well as statements related to our expectations regarding the performance of our business, including our ability to address macro and market conditions. Forward-looking statements involve known and unknown risks and uncertainties that may cause our actual results in future periods to differ materially from those projected or contemplated in the forward-looking statements. Investors should refer to Owens & Minor’s Annual Report on Form 10-K for the year ended December 31, 2024, expected to be filed with the SEC on or around February 28, 2025, including the section captioned “Item 1A. Risk Factors,” as applicable, and subsequent quarterly reports on Form 10-Q and current reports on Form 8-K filed with or furnished to the SEC, for a discussion of certain known risk factors that could cause the Company’s actual results to differ materially from its current estimates. These filings are available at www.owens-minor.com. Given these risks and uncertainties, Owens & Minor can give no assurance that any forward-looking statements will, in fact, transpire and, therefore, cautions investors not to place undue reliance on them. Owens & Minor specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.
About Owens & Minor
Owens & Minor, Inc. (NYSE: OMI) is a Fortune 500 global healthcare solutions company providing essential products and services that support care from the hospital to the home. For over 100 years, Owens & Minor and its affiliated brands, Apria®, Byram® and HALYARD*, have helped to make each day better for the patients, providers, and communities we serve. Powered by more than 20,000 teammates worldwide, Owens & Minor delivers comfort and confidence behind the scenes so healthcare stays at the forefront. Owens & Minor exists because every day, everywhere, Life Takes Care™. For more information about Owens & Minor and our affiliated brands, visit owens-minor.com or follow us on LinkedIn and Instagram.
* Registered Trademark or Trademark of O&M Halyard or its affiliates.
Exhibit 99.1 |
|||||||
Owens & Minor, Inc. |
|||||||
Consolidated Statements of Operations (unaudited) |
|||||||
(dollars in thousands, except per share data) |
|||||||
|
|
|
|
|
|
|
|
|
|
Three Months Ended December 31, |
|||||
|
|
2024 |
|
2023 |
|||
Net revenue |
|
$ |
2,696,073 |
|
|
$ |
2,656,150 |
Cost of goods sold |
|
|
2,116,307 |
|
|
|
2,086,227 |
Gross profit |
|
|
579,766 |
|
|
|
569,923 |
Distribution, selling and administrative expenses |
|
|
493,066 |
|
|
|
457,225 |
Goodwill impairment charge |
|
|
307,112 |
|
|
|
— |
Acquisition-related charges and intangible amortization |
|
|
25,148 |
|
|
|
26,427 |
Exit and realignment charges, net |
|
|
24,632 |
|
|
|
24,310 |
Other operating (income) expense, net |
|
|
(8,225 |
) |
|
|
1,940 |
Operating (loss) income |
|
|
(261,967 |
) |
|
|
60,021 |
Interest expense, net |
|
|
35,696 |
|
|
|
36,863 |
Loss on extinguishment of debt |
|
|
790 |
|
|
|
860 |
Other expense, net |
|
|
1,199 |
|
|
|
1,301 |
(Loss) income before income taxes |
|
|
(299,652 |
) |
|
|
20,997 |
Income tax (benefit) provision |
|
|
(3,535 |
) |
|
|
3,213 |
Net (loss) income |
|
$ |
(296,117 |
) |
|
$ |
17,784 |
|
|
|
|
|
|
|
|
Net (loss) income per common share: |
|
|
|
|
|
|
|
Basic |
|
$ |
(3.84 |
) |
|
$ |
0.23 |
Diluted |
|
$ |
(3.84 |
) |
|
$ |
0.23 |
Owens & Minor, Inc. |
||||||||
Consolidated Statements of Operations (unaudited) |
||||||||
(dollars in thousands, except per share data) |
||||||||
|
|
|
|
|
|
|
||
|
|
Years Ended December 31, |
||||||
|
|
2024 |
|
2023 |
||||
Net revenue |
|
$ |
10,700,883 |
|
|
$ |
10,333,967 |
|
Cost of goods sold |
|
|
8,481,728 |
|
|
|
8,208,806 |
|
Gross profit |
|
|
2,219,155 |
|
|
|
2,125,161 |
|
Distribution, selling and administrative expenses |
|
|
1,909,791 |
|
|
|
1,813,559 |
|
Goodwill impairment charge |
|
|
307,112 |
|
|
|
— |
|
Acquisition-related charges and intangible amortization |
|
|
86,543 |
|
|
|
101,037 |
|
Exit and realignment charges, net |
|
|
110,162 |
|
|
|
99,127 |
|
Other operating expense, net |
|
|
13,316 |
|
|
|
6,930 |
|
Operating (loss) income |
|
|
(207,769 |
) |
|
|
104,508 |
|
Interest expense, net |
|
|
143,804 |
|
|
|
157,915 |
|
Loss (gain) on extinguishment of debt |
|
|
1,101 |
|
|
|
(3,518 |
) |
Other expense, net |
|
|
4,683 |
|
|
|
4,837 |
|
Loss before income taxes |
|
|
(357,357 |
) |
|
|
(54,726 |
) |
Income tax provision (benefit) |
|
|
5,329 |
|
|
|
(13,425 |
) |
Net loss |
|
$ |
(362,686 |
) |
|
$ |
(41,301 |
) |
|
|
|
|
|
|
|
||
Net loss per common share: |
|
|
|
|
|
|
||
Basic |
|
$ |
(4.73 |
) |
|
$ |
(0.54 |
) |
Diluted |
|
$ |
(4.73 |
) |
|
$ |
(0.54 |
|
Owens & Minor, Inc. |
||||||
Condensed Consolidated Balance Sheets (unaudited) |
||||||
(dollars in thousands) |
||||||
|
|
|
|
|
|
|
|
|
December 31, |
|
December 31, |
||
|
|
2024 |
|
2023 |
||
Assets |
|
|
|
|
|
|
Current assets |
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
49,382 |
|
$ |
243,037 |
Accounts receivable, net |
|
|
690,241 |
|
|
598,257 |
Merchandise inventories |
|
|
1,131,879 |
|
|
1,110,606 |
Other current assets |
|
|
149,515 |
|
|
150,890 |
Total current assets |
|
|
2,021,017 |
|
|
2,102,790 |
Property and equipment, net |
|
|
509,347 |
|
|
543,972 |
Operating lease assets |
|
|
355,627 |
|
|
296,533 |
Goodwill |
|
|
1,331,281 |
|
|
1,638,846 |
Intangible assets, net |
|
|
298,726 |
|
|
361,835 |
Other assets, net |
|
|
140,158 |
|
|
149,346 |
Total assets |
|
$ |
4,656,156 |
|
$ |
5,093,322 |
Liabilities and equity |
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
Accounts payable |
|
$ |
1,251,964 |
|
$ |
1,171,882 |
Accrued payroll and related liabilities |
|
|
151,039 |
|
|
116,398 |
Current portion of long-term debt |
|
|
45,549 |
|
|
206,904 |
Other current liabilities |
|
|
425,187 |
|
|
396,701 |
Total current liabilities |
|
|
1,873,739 |
|
|
1,891,885 |
Long-term debt, excluding current portion |
|
|
1,808,047 |
|
|
1,890,598 |
Operating lease liabilities, excluding current portion |
|
|
286,212 |
|
|
222,429 |
Deferred income taxes, net |
|
|
22,456 |
|
|
41,652 |
Other liabilities |
|
|
100,476 |
|
|
122,592 |
Total liabilities |
|
|
4,090,930 |
|
|
4,169,156 |
Total equity |
|
|
565,226 |
|
|
924,166 |
Total liabilities and equity |
|
$ |
4,656,156 |
|
$ |
5,093,322 |
Owens & Minor, Inc. |
||||||||
Consolidated Statements of Cash Flows (unaudited) |
||||||||
(dollars in thousands) |
||||||||
|
|
|
|
|
|
|
||
|
|
Three Months Ended December 31, |
||||||
|
|
2024 |
|
2023 |
||||
Operating activities: |
|
|
|
|
|
|
||
Net (loss) income |
|
$ |
(296,117 |
) |
|
$ |
17,784 |
|
Adjustments to reconcile net (loss) income to cash provided by operating activities: |
|
|
|
|
|
|
||
Depreciation and amortization |
|
|
65,187 |
|
|
|
70,737 |
|
Goodwill impairment charge |
|
|
307,112 |
|
|
|
— |
|
Share-based compensation expense |
|
|
7,555 |
|
|
|
5,801 |
|
Loss on extinguishment of debt |
|
|
790 |
|
|
|
860 |
|
Deferred income tax benefit |
|
|
(10,996 |
) |
|
|
(7,333 |
) |
Changes in operating lease right-of-use assets and lease liabilities |
|
|
3,088 |
|
|
|
1,470 |
|
Gain from sales and dispositions of property and equipment |
|
|
(7,023 |
) |
|
|
(8,420 |
) |
Changes in operating assets and liabilities: |
|
|
|
|
|
|
||
Accounts receivable |
|
|
(33,663 |
) |
|
|
88,457 |
|
Merchandise inventories |
|
|
106,205 |
|
|
|
(22,719 |
) |
Accounts payable |
|
|
(99,074 |
) |
|
|
(15,341 |
) |
Net change in other assets and liabilities |
|
|
25,434 |
|
|
|
(22,497 |
) |
Other, net |
|
|
2,503 |
|
|
|
2,966 |
|
Cash provided by operating activities |
|
|
71,001 |
|
|
|
111,765 |
|
Investing activities: |
|
|
|
|
|
|
||
Additions to property and equipment |
|
|
(62,834 |
) |
|
|
(50,392 |
) |
Additions to computer software |
|
|
(8,602 |
) |
|
|
(5,933 |
) |
Proceeds from sales of property and equipment |
|
|
18,667 |
|
|
|
17,929 |
|
Other, net |
|
|
465 |
|
|
|
(518 |
) |
Cash used for investing activities |
|
|
(52,304 |
) |
|
|
(38,914 |
) |
Financing activities: |
|
|
|
|
|
|
||
Borrowings under amended Receivables Financing Agreement |
|
|
179,400 |
|
|
|
— |
|
Repayments under amended Receivables Financing Agreement |
|
|
(179,400 |
) |
|
|
— |
|
Borrowings under Revolving Credit Facility |
|
|
635,800 |
|
|
|
— |
|
Repayments under Revolving Credit Facility |
|
|
(635,800 |
) |
|
|
— |
|
Repayments of debt |
|
|
(32,750 |
) |
|
|
(50,504 |
) |
Other, net |
|
|
(10,346 |
) |
|
|
(711 |
) |
Cash used for financing activities |
|
|
(43,096 |
) |
|
|
(51,215 |
) |
Effect of exchange rate changes on cash, cash equivalents and restricted cash |
|
|
(1,309 |
) |
|
|
1,128 |
|
Net (decrease) increase in cash, cash equivalents and restricted cash |
|
|
(25,708 |
) |
|
|
22,764 |
|
Cash, cash equivalents and restricted cash at beginning of period |
|
|
75,090 |
|
|
|
250,160 |
|
Cash, cash equivalents and restricted cash at end of period(1) |
|
$ |
49,382 |
|
|
$ |
272,924 |
|
Supplemental disclosure of cash flow information: |
|
|
|
|
|
|
||
Income taxes (received) paid, net |
|
$ |
(2,057 |
) |
|
$ |
515 |
|
Interest paid |
|
$ |
37,269 |
|
|
$ |
52,168 |
|
Noncash investing activity: |
|
|
|
|
|
|
||
Unpaid purchases of property and equipment and computer software at end of period |
|
$ |
84,562 |
|
|
$ |
77,279 |
|
| _________________ | ||||||||
(1) There was no restricted cash as of December 31, 2024. Restricted cash as of September 30, 2024 was |
||||||||
Owens & Minor, Inc. |
||||||||
Consolidated Statements of Cash Flows (unaudited) |
||||||||
(dollars in thousands) |
||||||||
|
|
|
|
|
|
|
||
|
|
Years Ended December 31, |
||||||
|
|
2024 |
|
2023 |
||||
Operating activities: |
|
|
|
|
|
|
||
Net loss |
|
$ |
(362,686 |
) |
|
$ |
(41,301 |
) |
Adjustments to reconcile net loss to cash provided by operating activities: |
|
|
|
|
|
|
||
Depreciation and amortization |
|
|
264,775 |
|
|
|
287,377 |
|
Goodwill impairment charge |
|
|
307,112 |
|
|
|
— |
|
Share-based compensation expense |
|
|
26,836 |
|
|
|
23,218 |
|
Loss (gain) on extinguishment of debt |
|
|
1,101 |
|
|
|
(3,518 |
) |
Deferred income tax benefit |
|
|
(26,115 |
) |
|
|
(23,648 |
) |
Changes in operating lease right-of-use assets and lease liabilities |
|
|
10,244 |
|
|
|
(47 |
) |
Gain from sales and dispositions of property and equipment |
|
|
(44,705 |
) |
|
|
(34,882 |
) |
Changes in operating assets and liabilities: |
|
|
|
|
|
|
||
Accounts receivable |
|
|
(94,550 |
) |
|
|
165,167 |
|
Merchandise inventories |
|
|
(26,228 |
) |
|
|
224,338 |
|
Accounts payable |
|
|
65,187 |
|
|
|
30,997 |
|
Net change in other assets and liabilities |
|
|
30,153 |
|
|
|
100,370 |
|
Other, net |
|
|
10,371 |
|
|
|
12,639 |
|
Cash provided by operating activities |
|
|
161,495 |
|
|
|
740,710 |
|
Investing activities: |
|
|
|
|
|
|
||
Additions to property and equipment |
|
|
(210,865 |
) |
|
|
(190,870 |
) |
Additions to computer software |
|
|
(17,297 |
) |
|
|
(17,022 |
) |
Proceeds from sales of property and equipment |
|
|
103,426 |
|
|
|
71,574 |
|
Other, net |
|
|
8,203 |
|
|
|
(936 |
) |
Cash used for investing activities |
|
|
(116,533 |
) |
|
|
(137,254 |
) |
Financing activities: |
|
|
|
|
|
|
||
Borrowings under amended Receivables Financing Agreement |
|
|
1,465,800 |
|
|
|
476,000 |
|
Repayments under amended Receivables Financing Agreement |
|
|
(1,465,800 |
) |
|
|
(572,000 |
) |
Borrowings under Revolving Credit Facility |
|
|
635,800 |
|
|
|
— |
|
Repayments under Revolving Credit Facility |
|
|
(635,800 |
) |
|
|
— |
|
Repayments of debt |
|
|
(244,197 |
) |
|
|
(320,693 |
) |
Other, net |
|
|
(23,406 |
) |
|
|
(637 |
) |
Cash used for financing activities |
|
|
(267,603 |
) |
|
|
(417,330 |
) |
Effect of exchange rate changes on cash, cash equivalents and restricted cash |
|
|
(901 |
) |
|
|
613 |
|
Net (decrease) increase in cash, cash equivalents and restricted cash |
|
|
(223,542 |
) |
|
|
186,739 |
|
Cash, cash equivalents and restricted cash at beginning of period |
|
|
272,924 |
|
|
|
86,185 |
|
Cash, cash equivalents and restricted cash at end of period(1) |
|
$ |
49,382 |
|
|
$ |
272,924 |
|
Supplemental disclosure of cash flow information: |
|
|
|
|
|
|
||
Income taxes paid (received), net |
|
$ |
5,553 |
|
|
$ |
(6,283 |
) |
Interest paid |
|
$ |
141,547 |
|
|
$ |
153,247 |
|
Noncash investing activity: |
|
|
|
|
|
|
||
Unpaid purchases of property and equipment and computer software at end of period |
|
$ |
84,562 |
|
|
$ |
77,279 |
|
| _________________ | ||||||||
(1) There was no restricted cash as of December 31, 2024. Restricted cash as of December 31, 2023 was |
||||||||
Owens & Minor, Inc. |
||||||||||||||
Summary Segment Information (unaudited) |
||||||||||||||
(dollars in thousands) |
||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
Three Months Ended December 31, |
|
|||||||||||
|
|
2024 |
|
|
2023 |
|
||||||||
|
|
|
|
|
% of |
|
|
|
|
|
% of |
|
||
|
|
|
|
|
consolidated |
|
|
|
|
|
consolidated |
|
||
|
|
Amount |
|
net revenue |
|
|
Amount |
|
net revenue |
|
||||
Net revenue: |
|
|
|
|
|
|
|
|
|
|
|
|||
Products & Healthcare Services |
|
$ |
2,001,050 |
|
|
74.22 |
% |
$ |
1,991,716 |
|
|
74.99 |
% |
|
Patient Direct |
|
|
695,023 |
|
|
25.78 |
% |
|
664,434 |
|
|
25.01 |
% |
|
Consolidated net revenue |
|
$ |
2,696,073 |
|
|
100.00 |
% |
$ |
2,656,150 |
|
|
100.00 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
% of segment |
|
|
|
|
% of segment |
|
|||
Operating income: |
|
|
|
|
net revenue |
|
|
|
|
net revenue |
|
|||
Products & Healthcare Services |
|
$ |
25,825 |
|
|
1.29 |
% |
$ |
33,244 |
|
|
1.67 |
% |
|
Patient Direct |
|
|
69,558 |
|
|
10.01 |
% |
|
77,514 |
|
|
11.67 |
% |
|
Acquisition-related charges and intangible amortization |
|
|
(25,148 |
) |
|
|
|
|
(26,427 |
) |
|
|
|
|
Exit and realignment charges, net |
|
|
(24,632 |
) |
|
|
|
|
(24,310 |
) |
|
|
|
|
Goodwill impairment charge |
|
|
(307,112 |
) |
|
|
|
|
— |
|
|
|
|
|
Litigation and related charges (1) |
|
|
(458 |
) |
|
|
|
|
— |
|
|
|
|
|
Consolidated operating (loss) income |
|
$ |
(261,967 |
) |
|
|
|
$ |
60,021 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Depreciation and amortization: |
|
|
|
|
|
|
|
|
|
|
|
|||
Products & Healthcare Services |
|
$ |
11,407 |
|
|
|
|
$ |
12,019 |
|
|
|
|
|
Patient Direct |
|
|
34,959 |
|
|
|
|
|
36,685 |
|
|
|
|
|
Intangible amortization |
|
|
13,770 |
|
|
|
|
|
20,831 |
|
|
|
|
|
Other (2) |
|
|
5,051 |
|
|
|
|
|
1,202 |
|
|
|
|
|
Consolidated depreciation and amortization |
|
$ |
65,187 |
|
|
|
|
$ |
70,737 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Capital expenditures: |
|
|
|
|
|
|
|
|
|
|
|
|||
Products & Healthcare Services |
|
$ |
20,920 |
|
|
|
|
$ |
11,405 |
|
|
|
|
|
Patient Direct |
|
|
50,516 |
|
|
|
|
|
44,920 |
|
|
|
|
|
Consolidated capital expenditures |
|
$ |
71,436 |
|
|
|
|
$ |
56,325 |
|
|
|
|
|
(1) |
Litigation and related charges are reported within Other operating (income) expense, net in our Statements of Operations. Refer to footnote 4 in the GAAP/Non-GAAP Reconciliations below. |
|
(2) |
Other depreciation and amortization expense is captured within exit and realignment charges, net or acquisition-related charges and intangible amortization for the three months ended December 31, 2024 and 2023. |
Owens & Minor, Inc. |
||||||||||||||
Summary Segment Information (unaudited) |
||||||||||||||
(dollars in thousands) |
||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
Years Ended December 31, |
|
|||||||||||
|
|
2024 |
|
|
2023 |
|
||||||||
|
|
|
|
|
% of |
|
|
|
|
% of |
|
|||
|
|
|
|
|
consolidated |
|
|
|
|
consolidated |
|
|||
|
|
Amount |
|
net revenue |
|
Amount |
|
net revenue |
|
|||||
Net revenue: |
|
|
|
|
|
|
|
|
|
|
|
|||
Products & Healthcare Services |
|
$ |
8,020,771 |
|
|
74.95 |
% |
$ |
7,781,395 |
|
|
75.30 |
% |
|
Patient Direct |
|
|
2,680,112 |
|
|
25.05 |
% |
|
2,552,572 |
|
|
24.70 |
% |
|
Consolidated net revenue |
|
$ |
10,700,883 |
|
|
100.00 |
% |
$ |
10,333,967 |
|
|
100.00 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
% of segment |
|
|
|
|
% of segment |
|
|||
Operating income: |
|
|
|
|
net revenue |
|
|
|
|
net revenue |
|
|||
Products & Healthcare Services |
|
$ |
53,012 |
|
|
0.66 |
% |
$ |
57,809 |
|
|
0.74 |
% |
|
Patient Direct |
|
|
260,155 |
|
|
9.71 |
% |
|
246,863 |
|
|
9.67 |
% |
|
Acquisition-related charges and intangible amortization |
|
|
(86,543 |
) |
|
|
|
|
(101,037 |
) |
|
|
|
|
Exit and realignment charges, net |
|
|
(110,162 |
) |
|
|
|
|
(99,127 |
) |
|
|
|
|
Goodwill impairment charge |
|
|
(307,112 |
) |
|
|
|
|
— |
|
|
|
|
|
Litigation and related charges (1) |
|
|
(17,119 |
) |
|
|
|
|
— |
|
|
|
|
|
Consolidated operating (loss) income |
|
$ |
(207,769 |
) |
|
|
|
$ |
104,508 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Depreciation and amortization: |
|
|
|
|
|
|
|
|
|
|
|
|||
Products & Healthcare Services |
|
$ |
45,835 |
|
|
|
|
$ |
47,756 |
|
|
|
|
|
Patient Direct |
|
|
141,032 |
|
|
|
|
|
152,583 |
|
|
|
|
|
Intangible amortization |
|
|
64,943 |
|
|
|
|
|
83,522 |
|
|
|
|
|
Other (2) |
|
|
12,965 |
|
|
|
|
|
3,516 |
|
|
|
|
|
Consolidated depreciation and amortization |
|
$ |
264,775 |
|
|
|
|
$ |
287,377 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Capital expenditures: |
|
|
|
|
|
|
|
|
|
|
|
|||
Products & Healthcare Services |
|
$ |
50,050 |
|
|
|
|
$ |
29,361 |
|
|
|
|
|
Patient Direct |
|
|
178,112 |
|
|
|
|
|
178,531 |
|
|
|
|
|
Consolidated capital expenditures |
|
$ |
228,162 |
|
|
|
|
$ |
207,892 |
|
|
|
|
|
(1) |
Litigation and related charges are reported within Other operating (income) expense, net in our Statements of Operations. Refer to footnote 4 in the GAAP/Non-GAAP Reconciliations below. |
|
(2) |
Other depreciation and amortization expense is captured within exit and realignment charges, net or acquisition-related charges and intangible amortization for the years ended December 31, 2024 and 2023. |
Owens & Minor, Inc. |
|||||||||||||||
Net (Loss) Income Per Common Share (unaudited) |
|||||||||||||||
(dollars in thousands, except per share data) |
|||||||||||||||
|
|
Three Months Ended December 31, |
|
Years Ended December 31, |
|||||||||||
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
|||||||
Net (loss) income |
|
$ |
(296,117 |
) |
|
$ |
17,784 |
|
$ |
(362,686 |
) |
|
$ |
(41,301 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Weighted average shares outstanding - basic |
|
|
77,169 |
|
|
|
76,284 |
|
|
76,741 |
|
|
|
75,785 |
|
Dilutive shares |
|
|
— |
|
|
|
1,491 |
|
|
— |
|
|
|
— |
|
Weighted average shares outstanding - diluted |
|
|
77,169 |
|
|
|
77,775 |
|
|
76,741 |
|
|
|
75,785 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Net (loss) income per common share: |
|
|
|
|
|
|
|
|
|
|
|
|
|||
Basic |
|
$ |
(3.84 |
) |
|
$ |
0.23 |
|
$ |
(4.73 |
) |
|
$ |
(0.54 |
) |
Diluted |
|
$ |
(3.84 |
) |
|
$ |
0.23 |
|
$ |
(4.73 |
) |
|
$ |
(0.54 |
) |
Share-based awards of approximately 1.4 million and 1.5 million shares for the three months and year ended December 31, 2024 and 1.6 million for the year ended December 31, 2023 were excluded from the calculation of net loss per diluted common share as the effect would be anti-dilutive. |
|||||||||||||||
Owens & Minor, Inc. |
|||||||||||||||||
GAAP/Non-GAAP Reconciliations (unaudited) |
|||||||||||||||||
(dollars in thousands, except per share data) |
|||||||||||||||||
The following table provides a reconciliation of reported operating (loss) income, net (loss) income and net (loss) income per share to non-GAAP measures used by management. |
|||||||||||||||||
|
|
Three Months Ended December 31, |
Years Ended December 31, |
||||||||||||||
|
|
2024 |
2023 |
2024 |
2023 |
||||||||||||
Operating (loss) income, as reported (GAAP) |
|
$ |
(261,967 |
) |
$ |
60,021 |
|
$ |
(207,769 |
) |
$ |
104,508 |
|
||||
Acquisition-related charges and intangible amortization (1) |
|
|
25,148 |
|
|
26,427 |
|
|
86,543 |
|
|
101,037 |
|
||||
Exit and realignment charges, net (2) |
|
|
24,632 |
|
|
24,310 |
|
|
110,162 |
|
|
99,127 |
|
||||
Goodwill impairment charge (3) |
|
|
307,112 |
|
|
— |
|
|
307,112 |
|
|
— |
|
||||
Litigation and related charges (4) |
|
|
458 |
|
|
— |
|
|
17,119 |
|
|
— |
|
||||
Operating income, adjusted (non-GAAP) (Adjusted Operating Income) |
|
$ |
95,383 |
|
$ |
110,758 |
|
$ |
313,167 |
|
$ |
304,672 |
|
||||
Operating (loss) income as a percent of net revenue (GAAP) |
|
|
(9.72 |
)% |
|
2.26 |
% |
|
(1.94 |
)% |
|
1.01 |
% |
||||
Adjusted operating income as a percent of net revenue (non-GAAP) |
|
|
3.54 |
% |
|
4.17 |
% |
|
2.93 |
% |
|
2.95 |
% |
||||
|
|
|
|
|
|
|
|
|
|
||||||||
Net (loss) income, as reported (GAAP) |
|
$ |
(296,117 |
) |
$ |
17,784 |
|
$ |
(362,686 |
) |
$ |
(41,301 |
) |
||||
Pre-tax adjustments: |
|
|
|
|
|
|
|
|
|
||||||||
Acquisition-related charges and intangible amortization (1) |
|
|
25,148 |
|
|
26,427 |
|
|
86,543 |
|
|
101,037 |
|
||||
Exit and realignment charges, net (2) |
|
|
24,632 |
|
|
24,310 |
|
|
110,162 |
|
|
99,127 |
|
||||
Goodwill impairment charge (3) |
|
|
307,112 |
|
|
— |
|
|
307,112 |
|
|
— |
|
||||
Litigation and related charges (4) |
|
|
458 |
|
|
— |
|
|
17,119 |
|
|
— |
|
||||
Other (5) |
|
|
1,221 |
|
|
1,425 |
|
|
2,823 |
|
|
(1,260 |
) |
||||
Income tax benefit on pre-tax adjustments (6) |
|
|
(19,168 |
) |
|
(16,383 |
) |
|
(58,834 |
) |
|
(52,095 |
) |
||||
One-time income tax charge (7) |
|
|
— |
|
|
— |
|
|
17,233 |
|
|
— |
|
||||
Net income, adjusted (non-GAAP) (Adjusted Net Income) |
|
$ |
43,286 |
|
$ |
53,563 |
|
$ |
119,472 |
|
$ |
105,508 |
|
||||
|
|
|
|
|
|
|
|
|
|
||||||||
Net (loss) income per common share, as reported (GAAP) |
|
$ |
(3.84 |
) |
$ |
0.23 |
|
$ |
(4.73 |
) |
$ |
(0.54 |
) |
||||
After-tax adjustments: |
|
|
|
|
|
|
|
|
|
||||||||
Acquisition-related charges and intangible amortization (1) |
|
|
0.22 |
|
|
0.23 |
|
|
0.83 |
|
|
0.96 |
|
||||
Exit and realignment charges, net (2) |
|
|
0.21 |
|
|
0.22 |
|
|
1.04 |
|
|
0.95 |
|
||||
Goodwill impairment charge (3) |
|
|
3.95 |
|
|
— |
|
|
3.97 |
|
|
— |
|
||||
Litigation and related charges (4) |
|
|
— |
|
|
— |
|
|
0.17 |
|
|
— |
|
||||
Other (5) |
|
|
0.01 |
|
|
0.01 |
|
|
0.03 |
|
|
(0.01 |
) |
||||
One-time income tax charge (7) |
|
|
— |
|
|
— |
|
|
0.22 |
|
|
— |
|
||||
Net income per common share, adjusted (non-GAAP) (Adjusted EPS) |
|
$ |
0.55 |
|
$ |
0.69 |
|
$ |
1.53 |
|
$ |
1.36 |
|
||||
Owens & Minor, Inc. |
|||||||||||||||
GAAP/Non-GAAP Reconciliations (unaudited), continued |
|||||||||||||||
(dollars in thousands) |
|||||||||||||||
The following tables provide reconciliations of net (loss) income and total debt to non-GAAP measures used by management. |
|||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
Three Months Ended December 31, |
|
Years Ended December 31, |
|||||||||||
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
|||||||
Net (loss) income, as reported (GAAP) |
|
$ |
(296,117 |
) |
|
$ |
17,784 |
|
$ |
(362,686 |
) |
|
$ |
(41,301 |
) |
Income tax (benefit) provision |
|
|
(3,535 |
) |
|
|
3,213 |
|
|
5,329 |
|
|
|
(13,425 |
) |
Interest expense, net |
|
|
35,696 |
|
|
|
36,863 |
|
|
143,804 |
|
|
|
157,915 |
|
Acquisition-related charges and intangible amortization (1) |
|
|
25,148 |
|
|
|
26,427 |
|
|
86,543 |
|
|
|
101,037 |
|
Exit and realignment charges, net (2) |
|
|
24,632 |
|
|
|
24,310 |
|
|
110,162 |
|
|
|
99,127 |
|
Other depreciation and amortization (8) |
|
|
46,367 |
|
|
|
48,704 |
|
|
186,867 |
|
|
|
200,339 |
|
Litigation and related charges (4) |
|
|
458 |
|
|
|
— |
|
|
17,119 |
|
|
|
— |
|
Stock compensation (9) |
|
|
7,304 |
|
|
|
5,181 |
|
|
25,131 |
|
|
|
20,942 |
|
LIFO (credits) and charges (10) |
|
|
(10,074 |
) |
|
|
5,655 |
|
|
912 |
|
|
|
2,402 |
|
Goodwill impairment charge (3) |
|
|
307,112 |
|
|
|
— |
|
|
307,112 |
|
|
|
— |
|
Other (5) |
|
|
1,221 |
|
|
|
1,425 |
|
|
2,823 |
|
|
|
(1,260 |
) |
Adjusted EBITDA (non-GAAP) |
|
$ |
138,212 |
|
|
$ |
169,562 |
|
$ |
523,116 |
|
|
$ |
525,776 |
|
|
|
|
|
|
|
||
|
December 31, |
|
December 31, |
||||
|
2024 |
|
2023 |
||||
Total debt, as reported (GAAP) |
$ |
1,853,596 |
|
|
$ |
2,097,502 |
|
Cash and cash equivalents |
|
(49,382 |
) |
|
|
(243,037 |
) |
Net debt (non-GAAP) |
$ |
1,804,214 |
|
|
$ |
1,854,465 |
|
_________________
The following items have been excluded in our non-GAAP financial measures:
(1) Acquisition-related charges and intangible amortization for the three months and year ended December 31, 2024 includes
(2) During the three months and year ended December 31, 2024 exit and realignment charges, net were
(3) Goodwill impairment charge relates to a non-cash goodwill impairment charge recognized in the Apria reporting unit during the quarter ended December 31, 2024 resulting from a combination of factors, including fourth quarter 2024 market changes inclusive of a decline in Owens & Minor’s stock price and rising interest rates. Additionally, anticipated changes in pricing of a capitated contract within the Apria division also contributed to this charge. This is a non-cash charge and does not occur in the ordinary course of our business and is inherently unpredictable in timing and amount.
(4) Litigation and related charges includes settlement costs and related charges of legal matters within our Apria division. These costs do not occur in the ordinary course of our business, are non-recurring/infrequent and are inherently unpredictable in timing and amount.
(5) For the three months and year ended December 31, 2024 and 2023, other includes interest costs and net actuarial losses related to our frozen noncontributory, unfunded retirement plan for certain retirees in
(6) These charges have been tax effected by determining the income tax rate depending on the amount of charges incurred in different tax jurisdictions and the deductibility of those charges for income tax purposes.
(7) One-time income tax charge, recorded during the three months ended June 30, 2024, excluding the impact of incremental interest, relates to a recent decision associated with the Notice of Proposed Adjustments received in 2020 and 2021. The matter at hand, as discussed in previously filed SEC documents, is related to past transfer pricing methodology which is no longer employed. We believe the matter will be concluded without further impact to our financial results.
(8) Other depreciation and amortization relates to property and equipment and capitalized computer software, excluding such amounts captured within exit and realignment charges, net or acquisition-related charges and intangible amortization.
(9) Stock compensation includes share-based compensation expense related to our share-based compensation plans, excluding such amounts captured within exit and realignment charges, net or acquisition-related charges and intangible amortization.
(10) LIFO (credits) and charges includes non-cash adjustments to merchandise inventories valued at the lower of cost or market, with the approximate cost determined by the last-in, first-out (LIFO) method for distribution inventories in the
Use of Non-GAAP Measures
This earnings release contains financial measures that are not calculated in accordance with
Management provides these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on its financial and operating results and in comparing the Company’s performance to that of its competitors. However, the non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.
The non-GAAP financial measures disclosed by the Company should not be considered substitutes for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth above should be carefully evaluated.
OMI-CORP
OMI-IR
View source version on businesswire.com: https://www.businesswire.com/news/home/20250228859189/en/
Investors
Alpha IR Group
Jackie Marcus or Nick Teves
OMI@alpha-ir.com
Jonathan Leon
Executive Vice President & Chief Financial Officer
Investor.Relations@owens-minor.com
Media
Stacy Law
media@owens-minor.com
Source: Owens & Minor, Inc.
FAQ
What is Owens & Minor's (OMI) revenue guidance for 2025?
How much debt has OMI reduced in the past two years?
What is the size of OMI's newly authorized share repurchase program?
What is Owens & Minor's adjusted EPS guidance for 2025?
What strategic sale is Owens & Minor currently pursuing?
